Page last updated: 2024-08-24

fradafiban and aspirin

fradafiban has been researched along with aspirin in 3 studies

*Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) [MeSH]

*Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) [MeSH]

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (66.67)18.2507
2000's1 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Byrne, A; Crean, P; Fitzgerald, DJ; Maher, M; Moran, N; Walsh, N1
Bode, C; Kohler, B; Kübler, W; Moser, M; Nordt, T; Peter, K; Salbach, P; Schwarz, M; Ylänne, J1
Byrne, A; Cox, D; Crean, P; Fitzgerald, DJ; Kearney, D1

Trials

2 trial(s) available for fradafiban and aspirin

ArticleYear
Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty.
    Arteriosclerosis, thrombosis, and vascular biology, 1997, Volume: 17, Issue:11

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biphenyl Compounds; Bleeding Time; Cell Division; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinogen; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Muscle, Smooth, Vascular; P-Selectin; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombosis; Thromboxane A2; Thromboxane B2; Vasoconstriction

1997
Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor.
    Journal of the American College of Cardiology, 2004, Feb-18, Volume: 43, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Biphenyl Compounds; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprost; Epoprostenol; Female; Humans; Isoenzymes; Male; Membrane Proteins; Middle Aged; Peroxidases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prostaglandin-Endoperoxide Synthases; Pyrrolidines; Sulfonamides; Thromboxane A2

2004

Other Studies

1 other study(ies) available for fradafiban and aspirin

ArticleYear
Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
    Blood, 1998, Nov-01, Volume: 92, Issue:9

    Topics: Abciximab; Animals; Antibodies, Monoclonal; Aspirin; Binding, Competitive; Biphenyl Compounds; CHO Cells; Cricetinae; Disintegrins; Fibrinogen; Humans; Immunoglobulin Fab Fragments; Indomethacin; Mice; Oligopeptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Pyrrolidines; Recombinant Fusion Proteins

1998